FAST IMPACT Award
The FAST IMPACT Award funds major translational research to advance new therapies for Angelman syndrome from pre-clinical studies to IND-enabling stages, supporting innovative scientific approaches.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling (no fixed deadline)
Funding Amounts: Up to $1,000,000 per year; duration and total award based on project needs and review.
Summary: Supports comprehensive translational research advancing Angelman syndrome therapies from pre-clinical stages to IND-enabling studies.
Key Information: Letter of Intent required before full application; open to global nonprofit institutions.
Description
The FAST IMPACT Award, offered by the Foundation for Angelman Syndrome Therapeutics (FAST), provides substantial support for large-scale, translational research projects aimed at advancing therapeutic candidates for Angelman syndrome from pre-clinical stages to the point of Investigational New Drug (IND) application readiness. The program welcomes innovative approaches, including repurposing of approved or clinically safe therapies, with a particular focus on pharmacological, biologic, gene-editing, and gene replacement interventions. Projects should be comprehensive in scope and designed to accelerate the transition of promising concepts to clinical readiness, directly targeting the underlying mechanisms of Angelman syndrome.
